Trial Profile
Clinical study of Apatinib Mesylate Tablets unite Docetaxel in the Second-line treatment of EGFR Wild-type Advanced Non-Squamous Non-Small Cell Lung Cancer
Status:
Not yet recruiting
Phase of Trial:
Phase III/IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Rivoceranib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 08 Jul 2016 New trial record